ENDO 2026: GLP-1s Don't Harm Male Fertility — They May Improve It

The biggest male-specific GLP-1 news of the year just dropped at ENDO 2026. And it's the opposite of what most men feared.

The Finding

Scientists at the University Hospitals Coventry and Warwickshire presented a systematic review at ENDO 2026 — the Endocrine Society's annual meeting in Chicago — examining every published randomized controlled trial on GLP-1 medications and male reproductive function. Their conclusion: GLP-1 receptor agonists do not suppress the male hormonal axis and may actually improve reproductive hormones and semen parameters in obese men.

Specifically, a 24-week semaglutide trial showed improved sperm morphology and LDL cholesterol while preserving gonadotropins and total testosterone. A liraglutide weight-loss maintenance study reported improved sperm concentration and total count. A 16-week liraglutide trial in men with functional hypogonadism showed significant increases in total testosterone, LH, and FSH — and was superior to TRT for overall health outcomes.

Lead researcher Dr. Pratibha Natesh stated directly: "This work supports a shift away from prescribing testosterone replacement in men with obesity and low testosterone and toward treating the underlying cause — excess weight and poor metabolic health — which can naturally restore hormone levels and preserve fertility."

Why This Changes Everything for Men

Millions of men face a version of this dilemma: low testosterone symptoms (fatigue, low libido, difficulty building muscle, brain fog) driven by excess body weight. The standard medical response has been TRT — which works for symptoms but causes a 60.6% decrease in sperm concentration and effectively makes men infertile while on treatment.

GLP-1 medications attack the root cause. Excess body fat contains aromatase enzymes that convert testosterone to estrogen. Lose the fat, keep more testosterone. The ENDO 2026 data confirms this isn't theoretical — it's happening in clinical trials with measurable hormonal and fertility improvements.

For men planning families or wanting to preserve fertility options, this distinction is not academic. It's the difference between a treatment that improves one problem while creating another versus a treatment that addresses the underlying biology.

The Numbers That Matter

A separate ENDO study of 110 men with obesity showed that after 18 months on GLP-1 medications, the proportion with normal testosterone levels (above 300 ng/dL) rose from 53% to 77%. That's a 45% relative improvement in testosterone normalization without any exogenous hormone.

What You Should Do With This Information

If you're a man with a BMI over 30 and low testosterone symptoms, the ENDO 2026 data makes a strong case for trying GLP-1 treatment before — or instead of — TRT. If you're already on TRT and considering GLP-1 medications, discuss with your provider whether GLP-1-driven weight loss could eventually allow you to taper off TRT while maintaining healthy testosterone levels.

Either way, get baseline labs before starting: total testosterone, free testosterone, LH, FSH, SHBG, and estradiol. Then retest at 6 and 12 months. The data shows the improvement is real — but you need numbers to track it.